GSK lung cancer drug cuts death risk by 54% in trial
Rhea-AI Filing Summary
GSK plc (GSK) reported pivotal phase III data from the ARTEMIS-008 trial in China showing that B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) reduced the risk of death by 54% versus topotecan in relapsed small cell lung cancer after platinum-based therapy (HR 0.46; 95% CI: 0.35–0.62, p<0.0001).
Patients on Ris-Rez had median overall survival of 18.5 months compared with 10.3 months for topotecan, with consistent benefits across secondary endpoints: longer progression-free survival, higher objective response and disease control rates, and fewer grade ≥3 treatment-related adverse events. GSK holds exclusive rights outside Greater China and is running a broad global programme, including the phase III EMBOLD SCLC-301 trial with pivotal data expected next year.
Positive
- Ris-Rez cut risk of death by 54% versus topotecan in relapsed small cell lung cancer, with median overall survival of 18.5 vs 10.3 months, providing the first Phase III overall survival benefit reported for a B7-H3 antibody-drug conjugate.
- Efficacy was broad, with progression-free survival of 7.2 vs 3.0 months, objective response rate 58.3% vs 12.6% and disease control rate 90.4% vs 60.2% for Ris-Rez versus topotecan.
- Safety profile appears favourable, with grade ≥3 treatment-related adverse events in 60.9% vs 78.2% of patients on Ris-Rez versus topotecan, and events described as manageable and consistent with the class.
- GSK is leveraging these data in a broad global development programme across lung, prostate and other solid tumours, supported by multiple orphan drug, Breakthrough Therapy and PRIME designations that can facilitate regulatory pathways.
Negative
- None.
Key Figures
Risk of death reduction: 54% reduction (HR 0.46; 95% CI: 0.35–0.62)
Median overall survival – Ris-Rez: 18.5 months
Median overall survival – topotecan: 10.3 months
+5 more
8 metrics
Risk of death reduction
54% reduction (HR 0.46; 95% CI: 0.35–0.62)
Ris-Rez vs topotecan in ARTEMIS-008 after median 12.2 months’ follow-up
Median overall survival – Ris-Rez
18.5 months
Patients treated with Ris-Rez in ARTEMIS-008 (n=230)
Median overall survival – topotecan
10.3 months
Patients treated with topotecan in ARTEMIS-008 (n=231)
Median progression-free survival
7.2 vs 3.0 months
Ris-Rez vs topotecan, IRC-assessed in ARTEMIS-008
Objective response rate
58.3% vs 12.6%
IRC-assessed for Ris-Rez vs topotecan in ARTEMIS-008
Disease control rate
90.4% vs 60.2%
IRC-assessed for Ris-Rez vs topotecan in ARTEMIS-008
Grade ≥3 treatment-related adverse events
60.9% vs 78.2%
Ris-Rez vs topotecan in ARTEMIS-008
Patients treated with Ris-Rez globally
More than 1,000 patients
Cumulative participation in GSK’s EMBOLD clinical trial programme
Key Terms
overall survival, progression-free survival, objective response rate, disease control rate, +2 more
6 terms
overall survival medical
"The primary endpoint is statistically significant and clinically meaningful improvement in overall survival."
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
progression-free survival medical
"Median progression-free survival as assessed by an independent review committee (IRC) was 7.2 months versus 3.0 months."
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
objective response rate medical
"IRC-assessed objective response rate was 58.3% versus 12.6%."
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
disease control rate medical
"IRC-assessed disease control rate was 90.4% versus 60.2% for Ris-Rez and topotecan, respectively."
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
antibody-drug conjugate medical
"its pivotal phase III trial in China evaluating the B7-H3-targeted antibody-drug conjugate (ADC) risvutatug rezetecan."
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
Breakthrough Therapy Designation regulatory
"Ris-Rez has received several global regulatory designations to date, such as orphan drug designations and Breakthrough Therapy Designation."
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GSK (GSK) announce about Ris-Rez in small cell lung cancer?
GSK reported that phase III ARTEMIS-008 data in China showed Ris-Rez reduced risk of death by 54% versus topotecan in relapsed small cell lung cancer after platinum-based therapy, with median overall survival of 18.5 vs 10.3 months.
How did Ris-Rez perform on key efficacy endpoints versus topotecan for GSK (GSK)?
Ris-Rez achieved median progression-free survival of 7.2 vs 3.0 months, objective response rate 58.3% vs 12.6%, and disease control rate 90.4% vs 60.2% compared with topotecan in the ARTEMIS-008 trial.
What safety results did GSK (GSK) report for Ris-Rez in ARTEMIS-008?
Grade 3 or higher treatment-related adverse events occurred in 60.9% of patients on Ris-Rez versus 78.2% on topotecan. The most common severe events were haematologic and described as manageable and consistent with this medicine class.
What rights does GSK (GSK) hold for Ris-Rez and where is it being developed?
GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan, and is advancing a global programme across lung cancer, prostate cancer and other solid tumours.
What future trials of Ris-Rez is GSK (GSK) planning or running?
GSK’s EMBOLD programme includes a phase III trial in late-line extensive-stage small cell lung cancer and planned phase III trials in early-line small cell lung cancer and metastatic prostate cancers, with pivotal EMBOLD SCLC-301 data expected next year.
What regulatory designations has GSK’s Ris-Rez received?
Ris-Rez has received orphan drug designations for small cell lung cancer in the US, Japan and EU, plus US Breakthrough Therapy and EMA PRIME designations for relapsed or refractory extensive-stage small cell lung cancer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
